Supplied by CSL Seqirus[/caption]
Tahnee Simpson[/caption]
Nicolette Ellis MPS[/caption]
Ruth Nona[/caption]
High concentration topical capsaicin for chronic neuropathic pain
Neuropathic pain is associated with disability, reduced quality of life and employment, and increased healthcare costs.
The prevalence of neuropathic pain in the general...
Is Rikodeine still being rescheduled?
Last year, the TGA made an interim decision to reschedule Rikodeine to a prescription medicine. Why hasn’t it happened yet?
SHINGRIX now available to millions of vulnerable patients
From 1 November 2023, millions of Australians at risk of severe complications from shingles can receive a Shingrix vaccine under the NIP.
Do not supply Phenergan to children under 6, manufacturer warns
The TGA has worked with Phenergan manufacturer Sanofi to develop a new contraindication for the medicine in children under 6.
Therapeutic Guidelines overhaul UTI treatment
Expansive changes have been made to the Therapeutic Guidelines on antibiotics, encompassing over 1,400 drug recommendations.
Making sure patients and staff get through this COVID-19 wave
Australia is in the middle of another COVID-19 wave, with case numbers rising sharply since the end of October across the country.
